Targeted therapies for the prevention of lung cancer

Drugs of Today

Volumn 43, Issue 12, 2007, Pages 897-936

  Schachter, E Neil ^a   Neuman, Tzvi ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMFEBUTAMONE; BETA CAROTENE; BEVACIZUMAB; CELECOXIB; CISPLATIN; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PACLITAXEL; PEMETREXED; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PLATINUM COMPLEX; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOL; SELENIUM; TAMOXIFEN; UNINDEXED DRUG; VARENICLINE;

AIR POLLUTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DRUG ABSORPTION; DRUG DOSE COMPARISON; DYSPEPSIA; ENVIRONMENTAL EXPOSURE; FAMILY HISTORY; FLATULENCE; GENETIC ANALYSIS; HEADACHE; HICCUP; HISTOPATHOLOGY; HUMAN; HYPERSALIVATION; INSOMNIA; JAW ACHE; LOCAL SKIN REACTION; LOZENGE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUTH PAIN; NASAL IRRITATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE DISEASE; OCCUPATIONAL EXPOSURE; PAIN; REVIEW; RHINITIS; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SNEEZING; SPUTUM CYTODIAGNOSIS; TASTE DISORDER; THORAX RADIOGRAPHY; THROAT IRRITATION; UNSPECIFIED SIDE EFFECT; VIVID DREAM; WART VIRUS; XEROSTOMIA;

ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 38549133837     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.12.1088822     Document Type: Review

References (366)

1. Jemal, A., Murray, T., Samuels, A. et al. Cancer Statistics, 2003. CA Cancer J Clin 2003, 53(1): 5-26.
2. Jemal, A., Siegel, R., Ward, E., et al. Cancer Statistics, 2006. CA Cancer J Clin 2006, 56(2): 106-30.
3. Doll, R., Hill, A.B., A study of the aetiology of carcinoma of the lung. Br Med J 1952, 2(4797): 1271-86.
4. United States Surgeon General. Reducing the health consequences-25 years of progress: A Report of the Surgeon General. US Government Printing Office, 1989.
5. Lopez-Encuentra, A. Bronchogenic Carcinoma Co-operative Group. Comorbidity in operable lung cancer: A multi center descriptive study of 2992 patients. Lung Cancer 2002; 35(3): 263-9.
6. National Cancer Institute. Monograph 8; Changes in Cigarette-Related Disease Risks and Their Implication for Prevention and Control. National Institutes of Health, National Cancer Institute. NIH Publication No. 97-4213, February 1997, 395.
7. American Cancer Society: Cancer Facts and Figures 2006. Amer Cancer Soc 2006.
8. Fu, J., Ying Kau, T. Severson, et al. Lung cancer in women: Analysis of the national surveillance epidemiology, and end results (SEER) database. Chest 2005, 127(3): 768-77.
9. Kolonel, L.N., Henderson, B.E., Hankin, J.H. et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000, 151(4): 346-57.
10. Haiman, CA, Stram, DO, Wilkens,LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006, 354(4): 333-42.
11. Loganathan, R.S., Stover, D.E., Shi, W. et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006, 129(3): 1305-12.
12. Thomas, L., Doyle, L.A., Edelman, M.J. Lung cancer in women: Emerging differences in epidemiology, biology, and therapy. Chest 2005, 128(1): 370-81.
13. Patel, J.D., Bach, P.B., Kris, M.G. Lung cancer in US women: a contemporary epidemic. JAMA 2004, 291(14): 1763-68.
14. Dubey, S., Siegfried, J.M., Traynor, A.M. Non-small cell lung cancer and breast carcinoma: Chemotherapy and beyond. Lancet Oncol 2006, 7(5): 416-24.
15. Dhala, A., Pinsker, K., Prezant, D.J. Respiratory health consequences of environmental tobacco smoke. Clin Occup Environ Med 2006, 5(1) 139-56.
16. McDonald, J.C, McDonald A.D. Epidemiology of asbestos related lung cancer. In: Asbestos-related malignancy. Antmand K, Aisner, J (Eds). Orlando, Fl, Grune & Stratton: Orlando, Fl, 1987, 31-55.
17. Samet, J.M. Radon and lung cancer. J Natl Cancer Inst 1989, 81(10): 745-57.
18. Pasternack, B.S., Shore, R.E., Albert, R.E. Occupational exposure to chloromethyl ethers. A retrospective cohort mortality study (1948-1972). J Occup Med 1977, 19(11): 741-6.
19. Doll, R. Report of the international committee on nickel carcinogenesis in man. Scan J Work Env Health 1990, 16(1): 1.
20. Grimsrud, T.K., Berge, S.R., Haldorsen, T. et al. Exposure to different forms of nickel and risk of lung cancer. Am J Epidemiol 2002, 156(12): 1123-32.
21. Blot, W.J., Fraumeni, J.F. Jr. Arsenic and lung cancer. In: The Epidemiology of Lung Cancer. Samet, J. (Ed.) Marcell Dekker, New York 1994, 207-18.
22. Chen, Y.C., Chen, J.H., Richard, K. et al. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004, 101(6): 1428-36.
23. Raghu, G, Nyberg, F, Morgan, G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004, 91 (Suppl. 2): S3-S10.
24. Kiyohara, C., Yoshimasu, K., Shirkawa, T. et al. Genetic polymorphisms and Environ-mental risk of lung cancer: A review. Rev Eviron Health 2004, 19(1): 15-38.
25. United States Surgeon General. Reducing the health consequences-25 years of progress: A Report of the Surgeon General. US Government Printing Office 1989.
26. Burns, D.M. Primary prevention, smoking, and smoking cessation: Implications for future trends in lung cancer prevention. Cancer 2000, 89(Suppl.): 2506-9.
27. Graul, A.I., Prous, J.R. Executive summary: Nicotine addiction. Drugs Today 2005, 41(6): 419-25.
28. Stover, D.E. Prevention of lung cancer. Compr Ther 2003, 29(1): 28-34.
29. Hecht, S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002, 3(8): 461-9.
30. California Environmental Health Protection Agency. Health effects of exposure to environmental tobacco smoke: The report of the California Environmental Health Protection Agency. Smoking and tobacco control monograph number 10. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 1999 August.
31. Bero, L.A. Tobacco industry manipulation of research. Public Health Rep 2005, 120(2): 200-8.
32. Enstrom, J.E., Kabat, G.C. Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-98. BMJ 2003, 326(7398): 1057.
33. US Department of Health and Human Services. The health consequences of involuntary smoking. A report of the Surgeon General, 1986. Rockville Maryland: Public Health Service, Centers for Disease Control, 1986. (DHHS publication No (CDC) 87-8398.)
34. Diethelm, P.A., Rielle, J., McKee, M. The whole truth and nothing but the truth? The research that Phillip Morris did not want you to see. Lancet 2005, 336(9479): 86-92.
35. Schick, S., Glantz, S. Philip Morris toxicological experiments with fresh sidestream smoke: More toxic than mainstream smoke. Tobacco Control 2005, 14(6): 396-404.
36. Speizer, F.E., Samet, J.M. Air pollution and lung cancer. In: Epidemiology of Lung Cancer. Samet, J.M. (Ed.). Lung Biology in Health and Disease 1994, 74: 131-50.
37. World Cancer Report. Stewart, B.W., Kleihues, P. (Eds.) IARC Press 2003; 182-87.
38. Smith, K.R., Liu, Y. Indoor air pollution in developing countries. In: Epidemiology of Lung Cancer. Samet, J.M. Lung Biology in Health and Disease 1994, 74: 151-84.
39. Neuberger, J.S., Field, R.W. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003, 18(4): 251-67.
40. Pawel, D.J., Puskin, J.S. The US environmental protection agency's assessment of risks from indoor radon. Health Phys 2004, 87(1): 68-74.
41. Boffetta, P. Epidemiology of environmental and occupational cancer. Oncogene 2004, 23(38): 6392-403.
42. IARC (International Agency for Research on Cancer): Ionizing radiation, part 2: Some Internally Deposited Radionuclides, IARC Monographs on the Evaluation of Carcinogenic Risks to humans. IARC, Vol 28, 2001.
43. International Programme on Chemical Safety (IPCS). Chrysolite asbestos. Environmental Health Criteria. Vol 203. World Health Organization, 1998.
44. Weiss, W., Nash, D. An epidemic of lung cancer due to chloromethyl ethers: 30 years of observation. J Occup Environ Med 1997, 39(10): 1003-9.
45. ntp-server.niehs.nih.gov/ntp/roc/eleventh/profiles/s039bcme.pdf, accessed 10/27/06.
46. Hays, A.M., Srinivasan, D,, Witten, M.L. et al. Arsenic and cigarette smoke synergistically increase DNA oxidation in the lung. Toxicol Pathol 2006, 34(4): 396-404.
47. Grimsrud, T.K., Berge, S.R., Haldorsen, T. et al. Can lung cancer risk among nickel refinery workers be explained by occupational exposures other than nickel? Epidemiology 2005, 16(2): 146-54.
48. Callahan, W.P., Sutherland, J.C., Fulton, J.K. et al. Acute diffuse interstitial fibrosis of the lung. Arch Intern Med 1952, 90(4): 468-82.
49. Samet, J.M. Does Idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 2000, 161(1): 1-2.
50. Cheng, Y.-W., Chiou, H.-L., Sheu, G.-T. et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001, 61(7): 2799-803.
51. Lowy, D.R., Schiller, J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116(5): 1167-73.
52. Tokuhata, G.K., Lilienfeld, A.M. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963, 30(2): 289-312.
53. Samet, J., Humble, C., Pathak, D. Personal and family history of respiratory disease and lung cancer risk. Am Rev Resp Dis 1986, 134(3): 466-70.
54. Wu, A.H., Yu, M.C., Thomas, D.C. et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988, 48(24 Pt. 1): 7279-84.
55. Shaw, G.L., Falk, R.T., Pickle, L.W. et al. Lung cancer risk associated with cancer in relatives. J Clin Epidemiol 1991, 44(4-5): 429-37.
56. Osann, K.E. Lung cancer in women: the importance of smoking, family history of cancer and medical history of respiratory disease. Cancer Res 1991, 51(18): 4893-7.
57. Wu, A.H., Fontham, E.T., Reynolds, P. et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996, 143(6): 535-42.
58. Matakidou, A., Eisen, T., Houlston, R.S. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005, 93(7): 825-33.
59. Artinian, V., Kvale, P.A. Cancer and interstitial lung disease. Curr Opin Pulm Med 2004, 10(5): 425-34.
60. Bouros, D., Hatzakis, K., Labrakis, H. et al Association of malignancy with diseases causing interstitial pulmonary changes. Chest 2002, 121(4): 1278-89.
61. Papi, A., Casoni, G., Caramori, G. et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004, 59(8): 679-81.
62. rd Ed., Abeloff, M.D., Armitage, J.O., Niederhuber, J.E. (Eds.) 2004, 1649-743.
63. Mountain, C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111(6): 1710-7.
64. Jaklitsch, M.T., Strauss, G.M., Healy, E.A. et al. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer 1995, 12(Suppl. 2): S17-32.
65. Martini, N., Kris, M.G., Gralla, R.J. et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988, 45(4): 370-9.
66. Peck, K., Sher, Y., Shih, J. et al. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 1998, 58(13): 2761.
67. Aloia, T., Bepler, G., Harpole, D. et al. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Detect Prev 2001, 25(4): 336.
68. Schmitt, C.A. Senescence, apoptosis, and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003, 3(4): 286-95.
69. Gabay, C., Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6): 448-54.
70. Manser, R. Screening for lung cancer: A Review. Curr Opin Pulm Med 2004, 10(4): 266-71.
71. Manser, R., Irving, L.B., Byrnes, G. et al. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax 2003, 58(9): 784-9.
72. Manser, R., Irving, L.B., Byrnes, G. et al. Screening for lung cancer (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software 2001.
73. Fontana, R.S., Sanderson, D.R., Woolner, L.B. et al. Screening for lung cancer: a critique of the Mayo Lung Project. Cancer 1991, 67(Suppl. 4): 1155-64.
74. Wilde, J. A 10 year follow-up of semi-annual screening for early detection of; lung cancer in the Erfurt County, GDR. Eur Resp J 1989, 2(7): 656-62
75. Brett, G.Z. Earlier diagnosis and survival in lung cancer. BMJ 1969, 4(5678): 260-2.
76. Freidman, G., Collen, M.F., Fireman, B.H. Multiphasic health check up evaluation: A 16 year follow-up. J Chronic Dis 1986, 39(4): 453-63.
77. Kubik, A., Parkin, D.M., Khlat, M., et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990, 45(1): 26-33.
78. Bepler, G., Goodridge Carney, D.G., Djulbegovic, B., et al. A Systematic review and lessons learned from early lung cancer detection trials using low dose computed tomography of the chest. Cancer Control 2003, 10(4): 306-14.
79. Mulshine, J.L., Sullivan, D.C. Lung cancer screening. N Engl J Med 2005, 352(26): 2714-20.
80. The International Early Lung Cancer Action Program Investigators: Survival of Patients with Stage I Lung Cancer Detected on CT Screening. N Engl J Med 2006, 355(17): 1763-71.
81. Unger, M. A pause, progress, and reassessment in lung cancer screening. N Engl J Med 2006, 355(17): 1822-4.
82. U.S. Preventive services task force: Lung cancer screening: Recommendation statement. Ann Intern Med 2004(9), 140: 738-9.
83. Smith, R.A., Cokkinides, V., Eyre, H.J. American Cancer Society Guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004, 54(1): 41-52.
84. Saba, N.F., Khuri, F.R.: Chemoprevention strategies for patients with lung cancer in the context of screening. Clin Lung Cancer 2005;7(2): 92-99.
85. Chanin, T.D., Merrick, D.T., Franklin, W.A. et al. Recent Developments in Biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004, 10(4): 242-7.
86. Tockman, M.S., Zhukiv, T., Erozan, Y.S. et al. Antigen retrieval improves hnRNP A2/B1 immunohistochemical localization in premalignant lesions of the lung. In: Clinical and Biological Basis of Lung Cancer Prevention. Martinet, Y., Hirsch, E.R., Martinet, N. et al. (Eds.). Basil, Switzerland: Birkhauser 1998, 239-46.
87. Tockman, M.S., Mulshine, J.L., Piantadosi, S. et al. Prospective detection of clinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997, 3(12 Pt. 1): 2237-46.
88. Mills, N.E., Fishman, C.L., Scholes, J. et al. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995, 87(14): 1056-60.
89. Adrendt, S.A., Chow, J.T., Xu, L.H. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999, 91(4): 332-9.
90. Franklin, W.A., Gazdar, A.F., Haney, J. et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis [published erratum in J Clin Invest 1997, 100: 2639]. J Clin Invest 1997, 100(8): 2133-7.
91. Yakubovskaya, M.S., Spiegelman, V., Luo, F.C. et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995, 63(6): 810-4.
92. Sin, DD., Man, S.F.P., McWilliams, A. et al. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2006, 173(5): 535-9.
93. Malkinson, A.M. Evidence that inflammation encourages pulmonary adenocarcinoma formation in mice: clinical implications. Chest 2004, 125(Suppl. 5): 154S-5.
94. Bauer, A.K., Malkinson, A.M., Kleeberger, S.R. Susceptibility to neoplastic and nonneoplastic pulmonary diseases in mice: genetic similarities. Am Physiol Lung Cell Mol Physiol 2004, 287(4): L685-L703.
95. Gan, W.Q., Man, S.F., Senthilselvan, A. et al. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and meta-analysis. Thorax 2004, 59(7): 574-80.
96. Drent, M., Wimsberger, R.M., de Vries, J. et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999, 13(6): 718-22.
97. Mannino, D.M., Ford, E.S., Redd, S.C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003, 114(9): 758-62.
98. McKeown, D.J., Brown, D.J., Kelly, A. et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br J Cancer 2004, 91(12): 1993-5.
99. Forrest, L.M., McMillan, D.C., McArdle, C.S. et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2005, 92(10): 1834-6.
100. Chute, J.P., Chen, T., Feigal, E et al. Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999, 17(6): 1794-801.
101. Simon, G.R., Wagner, H. Small cell lung cancer. Chest 2003, 123: S259-71.
102. Albain, K.S., Crowley, J.J., LeBlanc, M. et al. Survival determinants in extensive-stage small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9(9): 1618-26.
103. Sandler, A.B. Chemotherapy for small cell lung cancer. Semin Oncol 2003, 30(1): 9-25.
104. National Cancer Institute: Non-Small Cell Lung Cancer (PDQ®): Treatment. http://www.cancer.gov/cancertopics/types/lung. Accessed 1/2/07.
105. Pirozynski, M. 100 years of lung cancer. Respir Med 2006, 100(12): 2073-84.
106. Mountain, C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111(6): 1710-7.
107. Pisters, K.M.W., Le Chevalier, T. Adjuvant chemotherapy in completely resected non-small cell lung cancer. J Clin Oncol 2005, 23(14): 3270-8.
108. Feld, R., Rubenstein, L.V., Weisenberger, T.H. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984, 2(12): 1352-8.
109. Immerman, S.C., Vanecko, R.M., Fry, W.A. et al. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981, 32(1): 23-7.
110. Betticher, D.C. Adjuvant and neoadjuvant chemotherapy in NSCLC: A paradigm shift. Lung Cancer 2005, 50(Suppl. 2): S9-S16.
111. Choong, N.W., Vokes, E.E. Adjuvant and Neoadjuvant Therapy for Early-Stage Non-small cell lung cancer. Clin Lung Cancer 2005, 7(Suppl. 3): S98-S104.
112. Furuse, K., Kubota, K., Kawahara, M. et al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995, 13(4): 869-75.
113. Albain, K.S., Rusch, V.W., Crowley, J.J. et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13(8): 1880-92.
114. Stuschke, M., Eberhardt, W., Pottgen, C. et al. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: Long Term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999, 17(9): 2700-9.
115. Strauss, G.M., Herndon, J.E., Sherman, D.D. et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992, 10(8): 1237-44.
116. Cox, J.D., Stanley, K., Petrovich, Z. et al. Cranial irradiation in cancer of the lung of all cell types. JAMA 1981, 245(5): 469-72.
117. Russell, A.H., Pajak, T.E., Selim, H.M. et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: Results of a prospective randomized trial conducted by Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991, 21(3): 637-43.
118. Umsawasdi, T., Valdivieso, M., Chen, T.T. et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 1984; 2(3): 253-259.
119. Skarin, A., Jochelson, M., Sheldon, T. et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long term follow-up in 41 patients. J Surg Oncol 1989, 40(4): 266-74.
120. Robnett, T.J., Machtay, M., Stevenson, J.P. et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small cell lung carcinoma. J Clin Oncol 2001, 19(5): 1344-9.
121. Law, A., Karp, D.D., Dipetrillo, T. et al. Emergence of increased cerebral metastasis after high dose preoperative radiotherapy with chemotherapy in patients with locally advanced non-small cell lung carcinoma. Cancer 2001, 92(1): 160-4.
122. Gaspar, L., Scott, C., Rotman, M. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37(4): 745-51.
123. Keith, B., Vincent, M., Stitt, L. et al. Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small cell lung cancer. Am J Clin Oncol 2002, 25(6): 583-7.
124. Komaki, R., Scott, C.B., Byhardt, R. et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four Radiation Therapy Oncology Group (ROTG) studies in inoperable non-mall cell lung cancer. Int J Radiat Oncol Biol Phys 1998, 42(2): 263-7.
125. Gaspar, L.E., Chansky, K., Albain, K.S. et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small cell lung cancer (NSCLC): A retrospective review by the Southwest Oncology Group (SWOG). J Clin Oncol 2005, 1: 23(13): 2955-61.
126. Cho, L.C., Dowell, J.E., Garwood, D. et al. Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol 2005, 32(3): 293-8.
127. Cox, J.D., Scott, C.B., Byhardt, R.W. et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of the lung (NSCLC): Analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999, 43(3): 505-9.
128. Furuse, K., Fukouka, M., Kawahara, M. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17(9): 2692-9.
129. Videtic, G.M., Johnson, B., Freidlin, B. et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Lung Cancer 2003, 41 (Suppl. 2):Abstr. S70.
130. Gandara, D.R., Chansky, K., Albain, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: Phase II Southwest Oncology Group study S9504. J Clin Oncol 2003, 21(10): 2004-10.
131. Choi, N.C., Carey, R.W., Daly, W. et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997, 15(2): 712-22.
132. Eagan, R.T., Ruud, C., Lee, R.E. et al. Pilot Study of induction therapy with cyclophosphamide, doxorubicin and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 1987, 71(10): 895-900.
133. Rusch, V.W., Griffin, B.R., Livingston, R.B. The role of prophylactic cranial irradiation in regionally advanced non-small cell lung cancer. A Southwest Oncology Group study. J Thorac Cardiovasc Surg 1989, 98(4): 535-9.
134. Laukkanen, E., Klonoof, H., Allan, B. et al. The role of prophylactic brain irradiation in limited stage small cell lung cancer: Clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 1988, 14(6): 1109-17.
135. Lishner, M., Feld, R., Payne, D.G. et al. Late neurological complications after prophylactic cranial irradiation inpatients with small-cell lung cancer: The Toronto Experience. J Clin Oncol 1990, 8(2): 215-21.
136. Twijnstra, A., Boon, P.J., Lormans, A.C. et al. Neurotoxicity of prophylactic cranial irradiation in patients with small cell lung carcinoma of the lung. Eur J Cancer 1987, 23(7): 983-6.
137. Van Oosterhout, A.G.M., Ganzevles, P.G.J., Wilmink, J.T. et al. Sequelae in long term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 1996, 34(5): 1037-44.
138. Johnson, B.E., Patronas, N., Hayes, W. et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small cell lung cancer: Further follow-up of 6-13 year survivors. J Clin Oncol 1990, 8(1): 48-56.
139. Fletcher, R.H., Fletcher, SW: Clinical Epidemiology: The Essentials. Lippincott Williams & Wilkins 2005, 148-9.
140. Halpern, M.T., Gillespie, B.W., Warner, K.E. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993, 85(6): 457-64.
141. Congolton, J., Muers, M.F. Incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness and response to bronchodilator therapy. Respir Med 1995, 89(4): 291-6.
142. Petty, T.L. Are COPD and lung cancer two manifestations of the same disease? Chest 2005, 128(4): 1895-7.
143. th edition.
144. Fiore, M.C., Bailey, W.C., Cohen, S.F. et al. Treating tobacco use and dependance: clinical practice Guideline. Department of Health and Human Services, Rockville, MD, USA. June 2000.
145. Fiore, M.C., Bailey, W.C., Cohen, S.J. et al. Treating tobacco use and dependance: Quick reference guide for clinicians. Rockville, MD: US Department of Health and Human Services, Public Health Service 2000.
146. Hughes, J.R., Stead, L.F., Lancaster, T. Antidepressants for smoking cessation. In: Cochrane Library. Chichester, England: John Wiley & Sons Ltd. 2006, issue 1.
147. Corelli, R.L., Hudmon, K.S. Pharmacologic interventions for smoking cessation. Crit Care Nurs Clin North Am 2006, 18(1): 39-51.
148. Silagy, C., Lancaster, T., Stead, L. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, (3): CD000146.
149. Hajek, P., West, R., Foulds, J. et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999, 159(17): 2033-8.
150. Fiore, M.C., Bailey, W.C., Cohen, S.J. et al. Treating tobacco use and dependence: clinical practice guideline. Rockville (MD): US Department of Health and Human Services, Public Health Service 2000.
151. Hurt, R.D., Sachs, D.P., Glover, E.D. et al. A comparison of sustained release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337: 1195-202.
152. Jorenby, D.E., Leischow, S.J., Nides, M.A. et al. A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340(9): 685-91.
153. Hays, J.T., Hurt, R.D., Rigotti, N.A. Sustained release bupropion for pharmacologic relapse prevention after smoking cessation: A randomized, controlled trial. Ann Intern Med 2001, 135(6): 423-33.
154. Gonzales, D., Rennard, S.I., Nides, M. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006, 296(1): 47-55.
155. Maskos, U., Molles, B.E., Pons, S. et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005, 436(7047): 103-7.
156. Di Chiara, G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000, 393(1-3: 295-314.
157. Tapper, A.R., McKinney, S.L., Nashmi, R. et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306(5698): 1029-32.
158. Pontieri, F.E., Tanda, G., Orzi, F. et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382(6588): 255-7.
159. Le Foll, B., Goldberg, S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005, 312(3): 875-83.
160. Sporn, M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976, 36: 2699-702.
161. Sporn, M.B., Dunlop, N.M., Newton, D.L. et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues [retinoids]. Fed Proc 1976, 35(6): 1332-8.
162. Fisher, B., Constantino, J.P., Wickerman, D.L. et al. Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90(18): 1371-88.
163. Hong, W.K., Endicott, J., Itri, L.M. et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315(24): 1501-5.
164. Hong, W.K., Lippman, S.M., Itri, L.M. et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990, 323(12): 795-801.
165. Steinbach, G., Lynch, P.M., Phillips, R.K. et al. The effects of celecoxib, a cyclo-oxygenase inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26): 1946-52.
166. Vogelstein, B., Fearon, E.R., Hamilton, S.R. et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988, 319(9): 525-32.
167. Westra, W.H., Slebos, R.J., Offerhaus, G.J. et al. K-ras oncogene activation in lung adenocarcinomas from former smokers: evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinomas of the lung. Cancer 1993, 72(2): 432-8.
168. Morkve, O., Halvorsen, O.J., Stangeland, I. et al. Quantitation of biological markers (p53, c-myc, Ki-67, and DNA ploidy) by multiparameter flow cytometry in non-small cell lung cancer. Int J Cancer 1992, 52(6):851-5.
169. Cohen, V., Khuri, F.R. Chemoprevention of lung cancer. Curr Opin Pulm Med 2004, 10(4): 279-83.
170. Slaughter, D.P., Southwick, H.W., Smejkal, W. Field Cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin. Cancer 1953, 6(5): 963-8.
171. Lippman, S.M., Hong, W.K. Molecular markers of the risk of oral cancer. N Engl J Med 2001, 344(17): 1323-6.
172. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82(1): 4-7.
173. Sandler, A.B. Targeting angiogenesis in lung cancer. Semin Oncol 2005, 32 (6 Suppl. 10): S16-S22.
174. Macchiarini, P., Fontanini, G., Hardin, M.J. et al. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 1992, 340(8812): 145-6.
175. Fontanini, G., Bigini, D., Vignati, S. et al. Microvessel count predicts metastatic disease and survival in non-small cell ling cancer. J Pathol 1995, 177(1): 57-63.
176. Fontanini, G., Lucchi, M., Vignati, S. et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study. J Natl Cancer Inst 1997, 89(12): 881-6.
177. Lucchi, M., Fontanini, G., Mussi, A. et al. Tumor angiogenesis and biologic markers in resected stage 1 NSCLC. Eur J Cardiothorac Surg 1997, 12: 535-41.
178. nd, et al. A biologic risk model for stage 1 lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999, 117(4): 736-43.
179. Cox, G., Walker, R.A., Andi, A. et al. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 2000, 29(3): 169-77.
180. O'Byrne, K.J., Koukourakis, M.I., Giatromanolaki, A. et al. Vascular endothelial growth factor, platelet derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer 2000, 82(8): 1427-32.
181. Yano, T., Tanikawa, S., Fujie, T et al. Vascular endothelial growth factor expression and neovascularization in non-small cell lung cancer. Eur J Cancer 2000, 36(5): 601-9.
182. Ushijima, C., Tsukamoto, S., Yamazaki, K. et al. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 2001, 34(2): 233-41.
183. Koukourakis, M.I., Giatromanolaki, K., Thorpe, P.E. et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000, 60(11): 3088-95.
184. Cohen, V., Khuri, F.R. Chemoprevention of lung cancer: Concepts and strategies. Expert Rev Anticancer Ther 2005, 5(3): 549-65.
185. Mavne, S.T., Lippman, S.M. Retinoids, carotenoids and micronuthents. In: Cancer: Principles and Practice of Oncology, Sixth Edition. Devita, V.T., Hellman, S., Rosenberg, S.A. (Eds.). USA 1997, 575-90.
186. Krinsky, N.I. Actions of carotenoids in biological systems. Annu Rev Nutr 1993, 13: 561-87.
187. Gudas, L.J., Hu, L. The regulation of gene expression by retinoids in normal and tumorigenic epithelial cells. Proc Annu Meet Am Assoc Cancer Res 1993, 34: 588-9.
188. Mangesdorf, D.J., Thummel, C., Beato, M. et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83(6): 835-9.
189. Mangesdorf, D.J., Umesono, K., Evans, R.M. The retinoid receptors. In: The Retinoids: Biology, Chemistry and Medicine. Second Edition. Sporn, M.B., Roberts, A.B., Goodman, D.S. (Eds.). NY, USA 1994, 319-49.
190. Wolbach, S.B., Howe, P.R. Tissue changes following deprivation of fat-soluble vitamin-A. J Exp Med 1935, 42(6): 753-77.
191. Muto, Y., Moriwaki, H., Ninomiya, M. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenicacid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24): 1561-7.
192. Benner, S.E., Pajak, T.F., Lippman, S.M. et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994, 86(2): 140-1.
193. Pastorino, U., Infante, M., Maioli, M. et al. Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 1993, 11 (7): 1216-22.
194. Peto, R., Doll, R., Buckley, J.D. et al. Can dietary β-carotene materially reduce human cancer rates. Nature 1981, 290: 201-8.
195. Floyd, R.A. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J. 1990, 4(9): 2587-97.
196. Chew, B.P., Wong, T.S., Shultz, T.D. et al. Effects of conjugated dienoic derivatives of linoleic acid and β-carotene in modulating lymphocyte and macrophage function. Anticancer Res 1997, 17(2A): 1099-106.
197. Murata, T., Tamai, H., Morinobu, T. et al. Effect of long-term administration of β-carotene on lymphocyte subsets in humans. Am J Clin Nutr 1994, 60(4): 597-602.
198. Toba, T., Shidoji, Y., Fujii, J. et al. Growth suppression and induction of heat shock protein-70 by 9-cis β-carotene in cervical dysplasia-derived cells. Life Sci 1997, 61(8): 839-45.
199. Muto, Y., Fujii, J., Shidoji, Y. et al. Growth retardation in human cervical dysplasia-derived cell lines by β-carotene through down-regulation of epidermal growth factor receptor. Amer J Clin Nutr 1995, 62(6 Suppl.): S1535-40.
200. Mariani, L., Formelli, F., De Palo G. et al. Chemoprevention of breast cancer with fenretinide (4-HPR); study of long-term visual and ophthalmologic tolerability. Tumori 1996, 82(5): 444-9.
201. Costa, A., Formelli, F., Chiesa, F. et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994, 54(Suppl. 7): 2032S-7S.
202. Dimery, I.W., Hong, W.K., Lee, J.J. et al. Phase I trial of α-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 1997, 8(1): 85-9.
203. Besa, E.C., Abrahm, J.L., Bartholomew, M.J. et al. Treatment with 13-cis-retinoic acid in transfusion dependent patients with myelodysplasia syndrome and decreased toxicity with addition of α-tocopherol. Am J Med 1990, 89(6): 739-47.
204. Nishino, H., Murakosh, M., Ii, T. et al. Carotenoids in cancer chemoprevention. Cancer Metastasis Rev 2002, 21(3-4): 257-64.
205. Rayman, M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutri Soc 2005, 64(4): 527-42.
206. nd edition, 2001. 498.
207. Rayman, M.P. The importance of selenium to human health. Lancet 2000, 356(9225): 233-41.
208. th Ed. Devlin, T.M. (Ed.). 2006, 730-3.
209. Zhuo, H., Smith, A.H., Steinmaus, C. Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 2004, 13(5): 771-8.
210. Davis, C.D., Finley, J.W. Chemical versus food forms of selenium in cancer prevention. In: Functional Foods and Nutraceuticals in Cancer Prevention, Watson, R.R. (Ed.), 2003, 55-85.
211. Ip, C., Lisk, D.J. Modulation of phase I and phase II xenobiotic-metabolizing enzymes by selenium enriched garlic in rats. Nutr Cancer 1997, 28(2): 184-8.
212. Jiang, C., Jiang, W., Ip, C. et al. Selenium induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999, 26(4): 213-25.
213. Jiang, C., Kim, K.H., Wang, Z. et al. Methyl selenium induced vascular endothelial apoptosis is executed by caspases and principally mediated by p38 MAPK pathway. Nutr Cancer 2004, 49(2): 174-83.
214. Karunasinghe, N., Ryan, J., Tuckey, J. et al. DNA stability and serum selenium levels in high risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(3): 391-7.
215. Kiremidjian-Schumacher, L., Roy, M., Glickman, R. et al. Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000, 73(2): 97-111.
216. Smith, M.L., Lancia, J.K., Mercer, T.I. et al. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Research 2004, 24(3a): 1401-8.
217. Schreinemachers, D.M., Everson, R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5(2): 138-46.
218. Steinbach, G., Lynch, P.M., Phillips, R.K. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26): 1946-52.
219. Mao, J.T., Cui, X., Reckamp, K. et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005, 7(1): 30-9.
220. Baron, J.A., Cole, B.F., Sandler, R.S. et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348(10): 891-9.
221. Benamouzig, R., Deyra, J., Martin, A. et al: Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of APACC trial. Gastroenterology 2003, 125(2): 328-36.
222. Sandler, R.S., Halabi, S., Baron, J.A. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348(10): 883-90.
223. Moysich, K.B., Menezes, RJ, Ronsani, A, et al: Regular aspirin use and lung cancer risk. BMC Cancer 2002, 2:31.
224. Eberhart, C.E., Coffey, R.J., Radhika, A. Upregulation of cyclo-oxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107(4): 1183-8.
225. Mao, J.T., Roth, M.D., Serio, K.J. et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res 2003, 9(16 Pt. 1): 5835-41.
226. Wolff, H., Saukkonen, K., Anttila, S. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58(22): 4997-5001.
227. Hida, T., Yatabe, Y., Achiwa, H. et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58(17): 3761-4.
228. Hosomi, Y., Yokose, T., Hirose, Y. et al. Increased ccyclooxygenase-2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinomas of the lung. Lung Cancer 2000, 30(2): 73-81.
229. Khuri, F.R., Wu, H., Lee, J.J. et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in Stage I nonsmall cell lung cancer. Clin Cancer Res 2001, 7(4): 861-7.
230. Han, S.W., Roman, J. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 2006, 51 (3): 283-96.
231. Tsubouchi, Y., Mukai, S., Kawahito, Y., et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000, 20(5A): 2867-72.
232. Bertagnolli, M.M., Eagle, C.J., Zauber, A.G. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9): 873-84.
233. Arber, N., Eagle, C.J., Spicak, J. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355(9): 885-95.
234. Psaty, B.M., Potter, J.D. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006, 355(9): 850-952.
235. M.D. Anderson News Release 07/01/05: M.D. Anderson Reactivates Lung Cancer Chemoprevention Trial with Celebrex. www.mdanderson.org/departments/ newsroom. Accessed 9/21/06.
236. Downs, J.R., Clearfeild, M., Weis, S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS; Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20): 1615-22.
237. Sheperd, J., Cobbe, S.M., Ford, I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. Atheroscler Suppl 2004, 5(3): 91-7.
238. Randomised trial of cholesterol lowering in 4444 patinets with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934): 1383-9.
239. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339(19): 1349-57.
240. Sacks, F.M., Pfeffer, M.A., Moye, L.A. et al. The effect of pravastation on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Inversigators. N Engl J Med 1996, 335(14): 1001-9.
241. Poynter, J.N., Gruber, S.B., Higgins, P.D. et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352(21): 2184-92.
242. Shannon, J., Tewoderos, S., Garzotto, M. et al. Statins and prostate cancer risk: a casecontrol study. Am J Epidemiol 2005, 162(4): 318-25.
243. Khurana, V., Bejjanki, H.R., Caldito, G. et al. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 2007, 131(5): 1282-8.
244. Huang, S.M., Harari, P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999, 17(3): 259-69.
245. Salamon, D.S., Brandt, R., Ciardiello, F. et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3): 183-232.
246. Richardson, C.M., Sharma, R.A., Cox, G. et al. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 2003, 39(1): 1-13.
247. Kurie, J.M., Shin, H.J.C., Lee, J.S. et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 199, 2(10): 1787-93.
248. Fontanini, G., Vignati, S., Bigini, D. et al. Epidermal Growth Factor Receptor (EGFR) expression in non-small cell lung cancer carcinomas correlate with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995, 31A(2): 178-83.
249. Mukaida, H., Toi, M., Hirari, T. et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991, 68(1): 142-8.
250. Neal, D.E., Mellon, K. Epidermal growth factor receptor and bladder cancer: A review. Urol Int 1992, 48(4): 365-71.
251. Sainsbury, J.R., Farndon, J.R., Needham, G.K. et al. Epidermal-growth factor receptor status as predictor of early occurrence of and death from breast cancer. Lancet 1987, 1(8547): 1398-402.
252. Rusch, V., Klimstra, D., Linkov, I. et al. Aberrant expression of p53 or the epidermal growth factor receptor in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 1995, 55(6): 1365-72.
253. Kabbinavar, F.F., Wong, J.T., Ayala, R.E. et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995, 36: 488 (Abstr. 2906).
254. Gossmann, A., Helbich, T.H., Kuriyama, N. et al. Dynamic contrast enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002, 15(3): 233-40.
255. Johnson, D.H., Fehrenbacher, L., Novotny, W.F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004, 22(11): 2184-91.
256. Sandler, A.B., Gray, R., Brahmer, J. et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung acncer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial-E4599. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23:16S.
257. Langer, C.J., Natale, R.B. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Onco 2005, 32 (Suppl. 10): S23-9.
258. Bollag, G., McCormick, F. Regulators and effectors of Ras proteins. Annu Rev Cell Biol 1991, 7: 601-32.
259. Kho, Y., Kim, S.C., Jiang, C. et al. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci, USA 2004, 101(34): 12479-84.
260. Rosell, R., Li, S., Skacel, Z. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993, 8(9): 2407-12.
261. Sebti, S.M., Hamilton, A.D. Fanesyltranferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench to bedside translational studies. Oncogene 2000, 19(56): 6584-93.
262. Zujewski, J., Horak, I.D., Bol, C.J. et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 200, 18(4): 927-41.
263. Westra, W.H., Baas, I.O., Hruban, R.H. et al. K-Ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996, 56(9): 2224-8.
264. Lantry, L.e., Zhang, Z., Yao, R. et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. Carcinogenesis 2000, 21(1): 113-6.
265. Schoonjans, K., Martin, G., Staels, B. et al. Peroxisome proliferator-activated receptors, orphans with ligand functions. Curr Opin Lipidol 1997, 8(3): 159-66.
266. Berger, J., Moller, D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53: 409-35.
267. Auwerx, J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999, 42(9): 1033-49.
268. Keshamouni, V.G., Reddy, R.C., Arenberg, D.A. et al. Peroxisome proliferator-activated receptor-I activation inhibits tumor progression in non-small cell lung cancer. Oncogene 2004, 23(1): 100-8.
269. Theocharis, S., Kanelli, H., Politi, A. et al. Expression of peroxisome proliferator-activated receptor-γ in non-small cell lung carcinoma: correlation with histologic type and grade. Lung Cancer 2002, 36: 249-55.
270. Segawa, Y., Yoshimura, R., Hase, T. et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 202, 51(2): 108-16.
271. Mueller, E., Sarraf, P., Tontonoz, P. et al. Terminal differentiation of human breast cancer through PPARI. Mol Cell 1998, 1(3): 465-70.
272. Boyle, J.O., Langenfeld, J., Lonardo, F. et al. Cydin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized and transformed human, bronchial epithelial cells. J Natl Cancer Inst 1999, 91(4): 373-9.
273. Witschi, H., Espiritu, I., Suffia, M. et al. Expression of CyclinD1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 2002, 23(2): 289-94.
274. Papadimitrakopoulou, V.A., Izzo, J., Mao, L. et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: Role in response to chemoprevention and cancer development. Clin Cancer Res 2001, 7(10): 3127-34.
275. Engler, T.A., Furness, K., Malhotra, S. et al. Novel, potent an selective Cyclin D1/CDK4 inhibitors: Indolo[6,7-a] pyrrolo[3,4-c]carbazoles. Bioorg Med Chem Lett 2003, 13: 2261-7.
276. Zochbauer-Muller, S., Minna, J.D., Gazdar, A.F. Aberrant DNA methylation in lung cancer: Biological and clinical implications. Oncologist 202, 7(5): 451-7.
277. Caraballoso, C., Sacristan, M., Serra, C. et al. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002141. DOI: 10.1002/14651858.CD002141.
278. Albanes, D., Heinonen, O.P., Taylor, P.R. et al. Alpha tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996, 88(21): 1560-70.
279. The Effect of Vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330(15): 1029-35.
280. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994, 4(1): 1-10.
281. Barnhart, S., Keogh, J., Cullen, M.R. et al. The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos exposed cohorts. Am J Ind Med 1997, 32(6): 573-81.
282. Chuwers, P., Barnhart, S., Blanc, P. et al. The protective effect of beta-carotene and retinol on ventilatory function in asbestos-exposed cohort. Am J Respir Crit Care Med 1997, 155(3): 1066-71.
283. Omenn, G.S., Goodman, G., Thornquist, M. et al. Risk factors for lung cancer and for intervention effects in CARET, The Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996, 88(21): 1550-9.
284. Omenn, G.S., Goodman, G.E., Thornquist, M.D. et al. Effects of a combination of beta-carotene and vitamin-A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334(18): 1150-5.
285. Omenn, G.S., Goodman, G.E., Thornquist, M.D. et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res 1994, 54 (Suppl. 7): 2038s-43s.
286. Thornquist, M.D., Omenn, G.S., Goodman, G.E. et al. Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). Control Clin Trials 1993, 14(4): 308-24.
287. Cook, N.R., Lee, I.M., Manson, J.E. et al. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physician's Health Study. Cancer Causes and Control 2000, 11(7): 617-26.
288. Hennkens, C.H., Eberlein, K. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 1985, 14(2): 165-8.
289. Hennekens, C.H., Buring, J., Manson, J. et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334(18): 1145-9.
290. The Steering Committee of the Physician's Health Study Research Group. Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988, 318(4): 262-4.
291. The Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321(3): 129-35.
292. Buring, J.E., Hennekens, C.H. The Women's Health Study: rationale and background. J Myocardial Ischemia 1992, 4: 30-40.
293. Buring, J.E., Hennekens, C.H. The Women's Health Study: summary and study design. J Myocardial Ischemia 1992, 4: 27-9.
294. Lee, I.M., Cook, N.R., Manson, J.E. et al. β-Carotene supplementation and the incidence of cancer and cardiovascular disease: The Women's Health Study. J Natl Cancer Inst 1999, 91(24): 2102-6.
295. Rexrode, K.M., Lee, I.M., Cook, N.R. et al. Baseline characteristics of participants in the Women's Health Study. J Women's Health Gend Based Med 2000, 9(1): 19-27.
296. Combs, G.F. Jr., Clark, L.C., Turnbull, B.W. et al. Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci 1997, 10(2-3): 227-34.
297. Patrick, L. Beta-carotene: The controversy. Altern Med Rev 2000, 5(6): 530-45.
298. Blot, W.J., Li, J.Y., Taylor, P.R. et al. Nutrition Intervention trials in linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 1993, 85(18): 1483-92.
299. Lee, J.S., Lippman, S.M., Benner, S.E. et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994, 12(5): 937-45.
300. Kurie, J.M., Lee, J.S., Khuri, F.R. et al. N-(4-hydroxyphenyl) Retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000, 6(8): 2973-9.
301. Arnold, A.M., Browman, G.P., Levine, M.N. et al. The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomized trial. Br J Cancer 1992, 65(5): 737-43.
302. McLarty, J.W., Holiday, D.B., Girard, W.M. et al. β-Carotene, vitamin-A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutr 1995, 62(Suppl. 6): S1431-S8.
303. Heimberger, D.C., Alexander, C.B., Birch, R., et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin-B12. Report of a preliminary randomized double blind intervention trial. JAMA 1988, 259(10): 1525-30.
304. Lippman, S.M., Benner, S.E., Hong, W.K. Cancer chemoprevention. J Clin Oncol 1994, 12(4): 851-73.
305. Kurie, J.M., Lotan, R., Lee, J.J. et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-b expression in the bronchial epithelium: results from a randomized placebo controlled trial. J Natl Cancer Inst 2003, 95(3): 206-14.
306. Khuri, F.R., Lotan, R., Kemp, B. et al. Retinoic acid receptor-β as a prognostic indicator in stage-l non-small cell lung cancer. J Clin Oncol 2000, 18(15): 2798-804.
307. Lam, S., MacAulay, C., Le Riche, J.C., et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002, 94: 1001-9.
308. van Zandwijk, N., Dalesio, O., Pastorino, U. et al. EUROSCAN, a randomized trial of Vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Co-operative Groups. J Natl Cancer Inst 2000, 92(12): 977-86.
309. Lippman, S.M., Lee, J.J., Karp, D.D. et al. Randomized Phase III intergroup trial of isotretinoin to prevent second primary tumors in Stage I non-small cell lung cancer. J Natl Cancer Inst 2001, 93(8): 605-18.
310. Virmani, A.K., Rathi, A., Zochbauer-Muller, S. et al. Promoter methylation and silencing of the retinoic acid receptor-b gene in lung carcinomas. J Natl Cancer Inst 2000, 92(16): 1303-7.
311. Clifford, J.L., Petkovich, M., Chambon, P. et al. Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells. Mol Endocrinol 1990, 4(10): 1546-55.
312. Lotan, R. Aberrant expression of retinoid receptors and lung carcinogenesis. J Natl Cancer Inst 1999, 91(12): 989-91.
313. Ayoub, J., Jean-Francois, R., Cormier, Y. et al. Placebo controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: Implications for chemoprevention of lung cancer. J Clin Oncol 1999, 17(11): 3546-52.
314. Ravi, R.K., Scott, F.M., Cuttitta, F. et al. Induction of gastrin-releasing peptide by all trans retinoic acid in small cell lung cancer cells. Oncol Rep 1998, 5(2): 497-501.
315. Siegfried, J.M., DeMichele, M.A., Hunt, J.D. et al. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells: Association with prolonged tobacco exposure and responsiveness to Bombesin-like peptides. Am J Respir Crit Care Med 1997, 156(2 Pt. 1): 358-66.
316. Manna, S.K., Aggarwal, B.B. All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apoptosis in human lung cancer cells. Onogene 2000, 19(17): 2110-9.
317. Pei, X.H., Nakanishi, Y., Takayama, K. et al. Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kB activity. J Biol Chem 1999, 274(49): 35240-6.
318. Winterhalder, R.C., Hirsch, F.R., Kotantoulas, W.A. et al. Chemoprevention of lung cancer-from biology to clinical reality. Ann Oncol 2004, 15(2): 185-96.
319. Ramalingam, S., Belani, C.P. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin Pharmacother 2005, 6(15): 2667-79.
320. Albanell, J., Rojo, F, Averbuch, S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20(1): 110-124.
321. Baselga, J., Rischin, D., Ranson, M. et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20(12): 4292-302.
322. Thatcher, N., Chang, A., Parikh, P. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496): 1527-37.
323. www.iressa-us.com/ Accessed 5/10/07.
324. Gatzemeier, U., Pluzanska, A., Szczesna, A. et al. Results of a Phase III trial of erlotinib (OSI -774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, Vol 22, No 14S (July 15 Suppl.), 2004: 7010.
325. Herbst, R.S., Prager, D., Hermann, R. et al. TRIBUTE- a Phase III trial of erlotinib HCl (OSI-744) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005, 23(25): 5892-9.
326. Baselga, J. The EGFR as a target for anticancer therapy- focus on cetuximab. Eur J Cancer 2001, 37(Suppl. 4): S16-S22.
327. Crawford, J., Sandler, A.B., Hammond, L.A. et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004, 22(Suppl. 14): 7083.
328. Schenkien, D.P. Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 2004, 6(Suppl. 2): S89-S96.
329. Mack, P.C., Davies, A.M., Lara, P.N. et al. Lung Cancer 2003, 41 (Suppl. 1): S89-S96.
330. Davies, A.M., Lara, P.N., Lau, D.H. et al. The proteosome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (15 Suppl. 15), 2004, 7106.
331. Davies, H., Bignall, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 41(6892)7: 949-54.
332. Strumberg, D., Richly, H., Hilger, R.A. et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor inhibitor bay-43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23(5): 965-72.
333. Sporn, M.B., Roberts, A.B. Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 1984, 73(6): 1381-7.
334. Mangelsdorf, D.J., Evans, R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83(6): 841-50.
335. Song, J.I., Lango, M.N., Hwang, J.D. et al. Abrogation of transforming growth factor- alpha/ epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD 1069, Targretin) in head and neck cancer cell lines. Cancer Res 2001, 61: 5919-25.
336. Blumenschein, G.R., Khuri, F.R., Gatzemeier, U. et al. A randomized Phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy naïve patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2005, 23: 621, Abstr. 7001.
337. Jassem, J., Zatloukal, P., Ramlau, R. et al. A randomized Phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy naïve patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2005, 23(Suppl.): 627s, Abstr. 7024.
338. Kuiper, G.G., Carlsson, B., Grandien, K. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138(3): 863-70.
339. Adams, G.P., Weiner, L.M. Monoclonal antibody therapy of cancer. Nature Biotechnology 2005, 23(9): 1147-57.
340. Korst, R.J., Crystal, R.G. Active, specific immunotherapy for lung cancer: Hurdles and strategies using genetic modification. Ann Thorac Surg 2003, 7(4)6: 1319-26.
341. th Ed. 1999, 115-62, 263-305, 550-60.
342. rd Ed. 1997, 115-37, 278-96, 382-405.
343. Gilboa, E. The makings of a tumor rejection antigen. Immunity 1999, 11(3): 263-70.
344. Toes, R.E.M., Offringa, R., Blom, R.J.J. et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci, USA 1996, 93(15): 7855-60.
345. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci, USA 1998, 95(3): 1178-83.
346. Parmiani, G., Rodolfo, M., Melani, C. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and reappraisal. Hum Gene Ther 2000, 1(9)1: 1269-75.
347. Roth, J.A., Swisher, S.G., Merritt, J.A. et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998, 25(3 Suppl. 8): 33-7.
348. Guo, J., Xin, H. Splicing out the west? Science 2006, 314(5803): 1232-5.
349. Hall, W. The prospects for immunotherapy in smoking cessation. Lancet 2002, 360(9339): 1089-91.
350. Pentel, P., Malin, D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 2002, 69(3): 193-7.
351. Kantak, K.M. Vaccines against drugs of abuse: a viable treatment option? Drugs 2003, 63(4): 341-52.
352. Hieda, Y., Keyler, D.E., Vandevoort, J.T. et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997, 283(3): 1076-81.
353. Pentel, P.R., Malin, D.H., Ennifar, S. et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000, 65(1): 191-8.
354. de Villiers, S.H., Lindblom, N., Kalayanov, G., et al. Active immunization against nicotine suppresses nicotine induced dopamine release in the rat nucleus accumbens shell. Respiration 2002, 69(3): 247-53.
355. Cerny, E.H., Levy, R., Mauel, J. et al. Preclinical development of a vaccine 'against smoking'. Onkologie 2002, 25(5): 406-11.
356. Lindblom, N., de Villiers, S.H., Semenova, S. et al. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol 2005, 372(3): 182-94.
357. Maurer, P., Jennings, G.T., Willers, J. et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005, 35(7): 2031-40.
358. Xenova Group Limited. TA-NIC. www.xenova.co.uk/dc_ta_nic.html. Accessed 8/29/06.
359. Johnson, B.A. New weapon to curb smoking: No more excuses to delay treatment. Arch Intern Med 2006, 166(15): 1547-50.
360. Fagerstrom, K., Balfour, D.J.K. Neuropharmacology and potential efficacy of new treatments for tobacco dependance. Expert Opin Investig Drugs 2006, 15(2): 107-16.
361. Alberts, W.M. Lung cancer guidelines: Introduction. Chest 2003, 123(Suppl. 1): 1S-2S.
362. Tobacco use - United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999, 48: 986-93.
363. Dragnev, K.H., Stover, D., Dmitrovsky, E. Lung cancer prevention: The guidelines. Chest 2003, 123(Suppl. 1): 60S-71S.
364. Marcus, R., Coulston, A.M. Fat-soluble vitamins: Vitamins A,K, and E. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition. Hardman, J.G., Limbird, L.E. et al. (Eds.) 2002, 1773-91.
365. Dwyer, J. Nutritional requirements and dietary assessment. In: Harrison's Priciples of Internal Medicine, 16th Edition. Kasper, D.L., Braunwald, E., Fauci, A.S. et al. (Eds.). USA 2005, 410.
366. Hughes, J., Stead, L., Lancaster, T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031. DOI: